Opinion|Videos|June 12, 2024
Treating Patients Referred to Academic Centers for CAR T
Focusing on the transition of patients from community practices to academic centers, the panel discusses the initial evaluation and treatment processes, focusing on bridging therapy for patients awaiting CAR T.
Advertisement
Episodes in this series
- From the academic center's perspective, how do you approach the initial consultation and evaluation process for patients referred for CAR T-cell therapy from community practices?
- Are the processes similar across academic settings?
- How do you coordinate care and maintain communication with the academic center during the CAR-T treatment period?
- What is your approach to bridging therapy for patients awaiting CAR-T? How do you decide on the appropriate bridging regimen?
- How closely do you coordinate with academic centers around bridging therapy considerations and processes?
Advertisement
Related to this article
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves OncoMate MSI Dx as Pembrolizumab Companion Diagnostic in MSI-H Solid Tumors
2
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumors
3
Hyperthermic Mitomycin C Yields 68% 1-Year HG-RFS in BCG-Unresponsive NMIBC
4
Acylfulvene Prodrug LP-184 Shows Tolerability in Recurrent Glioblastoma
5